The airways of patients with cystic fibrosis (CF) are nearly always infected with many
different microorganisms. This environment offers warm, humid and nutrient-rich conditions …

SUMMARY A select group of microorganisms inhabit the airways of individuals with cystic
fibrosis. Once established within the pulmonary environment in these patients, many of …

Objective This update of a 2007 guideline from the American Academy of Otolaryngology—
Head and Neck Surgery Foundation provides evidence-based recommendations to manage …

With rising antibiotic resistance, there has been increasing interest in treating pathogenic
bacteria with bacteriophages (phage therapy). One limitation of phage therapy is the ease at …

Abstract Background Therapy with Elexacaftor/Tezacaftor/Ivacaftor (ETI) was recently
approved for adult cystic fibrosis (CF) patients with at least one F508del mutation. However …

Pseudomonas aeruginosa is a remarkably versatile environmental bacterium with an
extraordinary capacity to infect the cystic fibrosis (CF) lung. Infection with P. aeruginosa …

The opportunistic pathogen Pseudomonas aeruginosa is a frequent colonizer of the airways
of patients suffering from cystic fibrosis (CF). Depending on early treatment regimens, the …

Chronic, pulmonary infections remain the single most prominent cause of the increased
morbidity and mortality in CF. After the increasing efficiency of anti-P. aeruginosa treatment …

Rationale: Cystic fibrosis (CF) is characterized by early structural lung disease caused by
pulmonary infections. The nasopharynx of infants is a major ecological reservoir of potential …

Immunoglobulin replacement therapy (IGRT) has contributed critically to the management of
primary antibody deficiencies (PAD) and the decrease in pneumonia rate. However, despite …